Belite Bio, Inc. ADR (D01)

Profile

https://www.belitebio.com

Belite Bio, Inc. ADR is a clinical-stage biopharmaceutical company focused on developing oral therapies for degenerative retinal diseases and selected metabolic disorders. Its lead candidate, Tinlarebant, is being studied for eye conditions such as Stargardt disease type 1 and geographic atrophy, with an emphasis on preserving retinal health and slowing disease progression. The company also develops LBS-009, a preclinical oral therapy aimed at metabolic diseases including liver disorders, type 2 diabetes, and gout. Belite Bio, Inc. ADR operates in the biotechnology and pharmaceuticals sector, where it contributes to the advancement of targeted treatments for conditions with significant unmet medical needs. The company is based in San Diego, California, and focuses on drug discovery and development centered on small-molecule therapeutics.